Despite 700% net product revenue growth to $113 million, ImmunityBio's high debt load and unprofitability remain significant ...

A newly developed radiopharmaceutical pair can precisely detect and effectively treat--completely eradicating tumors in ...

Researchers will use a quantitative continuous scoring platform to measure patients' tumors for TROP2 expression in the trial.

Ipsen (IPSEY) (IPSEF) shares traded higher in Paris on Wednesday after the U.S. FDA issued Breakthrough Therapy Designation ...

Argenx has announced that the US Food and Drug Administration has accepted for priority review a supplemental biologics ...

AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving ...

The firm expects Phase III data for its investigational selective estrogen receptor degrader camizestrant and its CLDN18.2 ADC sonesitatug vedotin this year.

Preliminary total global full year 2025 revenue of approximately $616 millionPreliminary BRIUMVI U.S. fourth quarter and full year 2025 net ...

In silico antibody accessibility analysis indicates that ectodomain epitopes are transiently exposed, while MPER epitopes are virtually always occluded in the pre-fusion trimer.

The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) compared ...

BURTON, MI, UNITED STATES, January 9, 2026 /EINPresswire.com/ -- Javelin Sciences, a pioneering certified biotechnology ...